News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations
Health & Biotech
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Experts
ScoPo’s Powerplays: Calmer week for ASX health stocks with some alarming stats about how many people drink instant coffee
Health & Biotech
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial
Health & Biotech
ASX Health Stocks: China likes Uscom device, includes it in national emergency guidelines
Health & Biotech
ASX Health Stocks: Immutep now patently Japanese; Patrys preps Phase 1 trial of brain cancer drug
Health & Biotech
ASX Health Stocks: ResApp gets FDA nod, while Japan grants Immutep a patent
Health & Biotech
ASX Health Stocks: Clarity Pharma gets the go-ahead from US FDA
Experts
ScoPo’s Powerplays: Who stands out in the enterprise imaging sector?
Health & Biotech
Here’s how Immutep and other immunotherapy biotechs have changed cancer treatment
Health & Biotech
ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2
News
Market Highlights and 5 ASX Small Caps to Watch on Friday
Experts
ScoPo’s Powerplays: Health stocks strap in for a ‘skittish’ ride
Health & Biotech
Check Up: Is biotech a good investment in a higher rate cycle? Turns out theory is just a theory
Health & Biotech
ScoPo’s Powerplays: Health stocks tumble but half-price sale presents buying opportunities
Health & Biotech
Who got what in the healthcare budget, and which ASX stocks could benefit
News